Case Study: Fortune 500 Biopharmaceutical Company achieves reduced endpoint tool sprawl and optimized endpoint security with SafeBreach

Fortune 500 Biopharmaceutical Company Reduces Endpoint Tool Sprawl With SafeBreach

The Fortune 500 Biopharmaceutical Company faced growing endpoint tool sprawl—many overlapping security agents that increased complexity, degraded user performance, and left uncertainty about actual protection. To obtain continuous security control validation and actionable visibility, the security team deployed SafeBreach and its platform to run safe, automated attack simulations against their endpoint environment.

SafeBreach automated repeatable attack playbooks against clean images and incremental tool configurations so the team could see which tools stopped which attacks, prioritize vulnerabilities, and remove or consolidate ineffective agents. Using SafeBreach, the organization improved testing consistency and operational efficiency, gained clear insights to address tool sprawl, and realized a strong ROI (the CISO cited the potential to reduce endpoint tools from about 15 to 5) while strengthening overall safeguards.